Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance

Rita Humeniuk, Lata G. Menon, Prasun J. Mishra, Richard Gorlick, Rebecca Sowers, Wojciech Rode, Giuseppe Pizzorno, Yung Chi Cheng, Nancy Kemeny, Joseph R. Bertino, Debabrata Banerjee

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

5-Fluorouracil (5-FU) continues to be widely used for treatment of gastrointestinal cancers. Because many tumors show primary or acquired resistance, it is important to understand the molecular basis underlying the mechanism of resistance to 5-FU. In addition to its effect on thymidylate synthase inhibition and DNA synthesis, 5-FU may also influence RNA metabolism. Our previous studies revealed that colorectal cancer cells resistant to bolus 5-FU (HCT-8/4hFU) showed significantly decreased incorporation of the drug into RNA. Resistance to bolus 5-FU was associated with lower expression of UMP kinase (UMPK), an enzyme that plays an important role in the activation of 5-FU to 5-FUTP and its incorporation into RNA. Activities of other 5-FU-metabolizing enzymes (e.g., thymidine kinase, uridine phosphorylase, thymidine phosphorylase, and orotate phosphoribosyltransferase) remained unchanged between sensitive and resistant cell lines. Herein, we show that UMPK down-regulation in 5-FU-sensitive cells (HCT-8/P) induces resistance to bolus 5-FU treatment. Moreover, HCT-8/4hFU cells are even more cross-resistant to treatment with 5-fluorouridine, consistent with the current understanding of 5-fluorouridine as a RNA-directed drug. Importantly, colorectal cancer hepatic metastases isolated from patients clinically resistant to weekly bolus 5-FU/leucovorin treatment exhibited decreased mRNA expression of UMPK but not thymidylate synthase or dihydropyrimidine dehydrogenase compared with tumor samples of patients not previously exposed to 5-FU. Our findings provide new insights into the mechanisms of acquired resistance to 5-FU in colorectal cancer and implicate UMPK as an important mechanism of clinical resistance to pulse 5-FU treatment in some patients.

Original languageEnglish (US)
Pages (from-to)1037-1044
Number of pages8
JournalMolecular Cancer Therapeutics
Volume8
Issue number5
DOIs
StatePublished - May 1 2009

Fingerprint

Fluorouracil
RNA
Colorectal Neoplasms
Thymidylate Synthase
uridine monophosphate kinase
Orotate Phosphoribosyltransferase
Uridine Phosphorylase
Dihydrouracil Dehydrogenase (NADP)
Thymidine Phosphorylase
Therapeutics
Gastrointestinal Neoplasms
Leucovorin
Thymidine Kinase
Enzymes
Pharmaceutical Preparations
Neoplasms
Down-Regulation
Neoplasm Metastasis
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Humeniuk, R., Menon, L. G., Mishra, P. J., Gorlick, R., Sowers, R., Rode, W., ... Banerjee, D. (2009). Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Molecular Cancer Therapeutics, 8(5), 1037-1044. https://doi.org/10.1158/1535-7163.MCT-08-0716

Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. / Humeniuk, Rita; Menon, Lata G.; Mishra, Prasun J.; Gorlick, Richard; Sowers, Rebecca; Rode, Wojciech; Pizzorno, Giuseppe; Cheng, Yung Chi; Kemeny, Nancy; Bertino, Joseph R.; Banerjee, Debabrata.

In: Molecular Cancer Therapeutics, Vol. 8, No. 5, 01.05.2009, p. 1037-1044.

Research output: Contribution to journalArticle

Humeniuk, R, Menon, LG, Mishra, PJ, Gorlick, R, Sowers, R, Rode, W, Pizzorno, G, Cheng, YC, Kemeny, N, Bertino, JR & Banerjee, D 2009, 'Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance', Molecular Cancer Therapeutics, vol. 8, no. 5, pp. 1037-1044. https://doi.org/10.1158/1535-7163.MCT-08-0716
Humeniuk, Rita ; Menon, Lata G. ; Mishra, Prasun J. ; Gorlick, Richard ; Sowers, Rebecca ; Rode, Wojciech ; Pizzorno, Giuseppe ; Cheng, Yung Chi ; Kemeny, Nancy ; Bertino, Joseph R. ; Banerjee, Debabrata. / Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 5. pp. 1037-1044.
@article{344055b4c15f4df9844b00aad34e0c26,
title = "Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance",
abstract = "5-Fluorouracil (5-FU) continues to be widely used for treatment of gastrointestinal cancers. Because many tumors show primary or acquired resistance, it is important to understand the molecular basis underlying the mechanism of resistance to 5-FU. In addition to its effect on thymidylate synthase inhibition and DNA synthesis, 5-FU may also influence RNA metabolism. Our previous studies revealed that colorectal cancer cells resistant to bolus 5-FU (HCT-8/4hFU) showed significantly decreased incorporation of the drug into RNA. Resistance to bolus 5-FU was associated with lower expression of UMP kinase (UMPK), an enzyme that plays an important role in the activation of 5-FU to 5-FUTP and its incorporation into RNA. Activities of other 5-FU-metabolizing enzymes (e.g., thymidine kinase, uridine phosphorylase, thymidine phosphorylase, and orotate phosphoribosyltransferase) remained unchanged between sensitive and resistant cell lines. Herein, we show that UMPK down-regulation in 5-FU-sensitive cells (HCT-8/P) induces resistance to bolus 5-FU treatment. Moreover, HCT-8/4hFU cells are even more cross-resistant to treatment with 5-fluorouridine, consistent with the current understanding of 5-fluorouridine as a RNA-directed drug. Importantly, colorectal cancer hepatic metastases isolated from patients clinically resistant to weekly bolus 5-FU/leucovorin treatment exhibited decreased mRNA expression of UMPK but not thymidylate synthase or dihydropyrimidine dehydrogenase compared with tumor samples of patients not previously exposed to 5-FU. Our findings provide new insights into the mechanisms of acquired resistance to 5-FU in colorectal cancer and implicate UMPK as an important mechanism of clinical resistance to pulse 5-FU treatment in some patients.",
author = "Rita Humeniuk and Menon, {Lata G.} and Mishra, {Prasun J.} and Richard Gorlick and Rebecca Sowers and Wojciech Rode and Giuseppe Pizzorno and Cheng, {Yung Chi} and Nancy Kemeny and Bertino, {Joseph R.} and Debabrata Banerjee",
year = "2009",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-08-0716",
language = "English (US)",
volume = "8",
pages = "1037--1044",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance

AU - Humeniuk, Rita

AU - Menon, Lata G.

AU - Mishra, Prasun J.

AU - Gorlick, Richard

AU - Sowers, Rebecca

AU - Rode, Wojciech

AU - Pizzorno, Giuseppe

AU - Cheng, Yung Chi

AU - Kemeny, Nancy

AU - Bertino, Joseph R.

AU - Banerjee, Debabrata

PY - 2009/5/1

Y1 - 2009/5/1

N2 - 5-Fluorouracil (5-FU) continues to be widely used for treatment of gastrointestinal cancers. Because many tumors show primary or acquired resistance, it is important to understand the molecular basis underlying the mechanism of resistance to 5-FU. In addition to its effect on thymidylate synthase inhibition and DNA synthesis, 5-FU may also influence RNA metabolism. Our previous studies revealed that colorectal cancer cells resistant to bolus 5-FU (HCT-8/4hFU) showed significantly decreased incorporation of the drug into RNA. Resistance to bolus 5-FU was associated with lower expression of UMP kinase (UMPK), an enzyme that plays an important role in the activation of 5-FU to 5-FUTP and its incorporation into RNA. Activities of other 5-FU-metabolizing enzymes (e.g., thymidine kinase, uridine phosphorylase, thymidine phosphorylase, and orotate phosphoribosyltransferase) remained unchanged between sensitive and resistant cell lines. Herein, we show that UMPK down-regulation in 5-FU-sensitive cells (HCT-8/P) induces resistance to bolus 5-FU treatment. Moreover, HCT-8/4hFU cells are even more cross-resistant to treatment with 5-fluorouridine, consistent with the current understanding of 5-fluorouridine as a RNA-directed drug. Importantly, colorectal cancer hepatic metastases isolated from patients clinically resistant to weekly bolus 5-FU/leucovorin treatment exhibited decreased mRNA expression of UMPK but not thymidylate synthase or dihydropyrimidine dehydrogenase compared with tumor samples of patients not previously exposed to 5-FU. Our findings provide new insights into the mechanisms of acquired resistance to 5-FU in colorectal cancer and implicate UMPK as an important mechanism of clinical resistance to pulse 5-FU treatment in some patients.

AB - 5-Fluorouracil (5-FU) continues to be widely used for treatment of gastrointestinal cancers. Because many tumors show primary or acquired resistance, it is important to understand the molecular basis underlying the mechanism of resistance to 5-FU. In addition to its effect on thymidylate synthase inhibition and DNA synthesis, 5-FU may also influence RNA metabolism. Our previous studies revealed that colorectal cancer cells resistant to bolus 5-FU (HCT-8/4hFU) showed significantly decreased incorporation of the drug into RNA. Resistance to bolus 5-FU was associated with lower expression of UMP kinase (UMPK), an enzyme that plays an important role in the activation of 5-FU to 5-FUTP and its incorporation into RNA. Activities of other 5-FU-metabolizing enzymes (e.g., thymidine kinase, uridine phosphorylase, thymidine phosphorylase, and orotate phosphoribosyltransferase) remained unchanged between sensitive and resistant cell lines. Herein, we show that UMPK down-regulation in 5-FU-sensitive cells (HCT-8/P) induces resistance to bolus 5-FU treatment. Moreover, HCT-8/4hFU cells are even more cross-resistant to treatment with 5-fluorouridine, consistent with the current understanding of 5-fluorouridine as a RNA-directed drug. Importantly, colorectal cancer hepatic metastases isolated from patients clinically resistant to weekly bolus 5-FU/leucovorin treatment exhibited decreased mRNA expression of UMPK but not thymidylate synthase or dihydropyrimidine dehydrogenase compared with tumor samples of patients not previously exposed to 5-FU. Our findings provide new insights into the mechanisms of acquired resistance to 5-FU in colorectal cancer and implicate UMPK as an important mechanism of clinical resistance to pulse 5-FU treatment in some patients.

UR - http://www.scopus.com/inward/record.url?scp=66849132243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66849132243&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0716

DO - 10.1158/1535-7163.MCT-08-0716

M3 - Article

VL - 8

SP - 1037

EP - 1044

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -